Nations Financial Group Inc. IA ADV acquired a new stake in shares of AstraZeneca PLC (OTCMKTS:AZNCF – Free Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 3,626 shares of the company’s stock, valued at approximately $715,000.
Other hedge funds have also added to or reduced their stakes in the company. Seven Mile Advisory purchased a new position in shares of AstraZeneca in the 4th quarter worth about $738,000. L & S Advisors Inc purchased a new stake in AstraZeneca during the 4th quarter valued at about $14,863,000. Monetary Management Group Inc. bought a new stake in AstraZeneca during the 4th quarter valued at about $1,097,000. Oarsman Capital Inc. bought a new stake in AstraZeneca during the 4th quarter valued at about $5,027,000. Finally, Hendley & Co. Inc. purchased a new position in AstraZeneca in the fourth quarter worth about $11,373,000. 40.87% of the stock is owned by institutional investors.
AstraZeneca Stock Performance
Shares of OTCMKTS AZNCF opened at $187.10 on Wednesday. The firm’s 50 day moving average price is $187.10 and its 200-day moving average price is $186.15. AstraZeneca PLC has a 52-week low of $122.26 and a 52-week high of $195.00.
AstraZeneca Profile
AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.
The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.
Featured Stories
- Five stocks we like better than AstraZeneca
- Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning
- Apple’s Intel Deal Arrives at the Right Time for Its Stock
- Liquid Gold: The AI Cooling Retrofit Trade
- 3 Dividend Stocks Under $30 to Anchor Your Portfolio
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
